| Autor: |
Kugler, Eitan, Madiwale, Shreyas, Yong, Darren, Thoms, Julie A. I., Birger, Yehudit, Sykes, David B., Schmoellerl, Johannes, Drakul, Aneta, Priebe, Valdemar, Yassin, Muhammad, Aqaqe, Nasma, Rein, Avigail, Fishman, Hila, Geron, Ifat, Chen, Chun-Wei, Raught, Brian, Liu, Qiao, Ogana, Heather, Liedke, Elisabeth, Bourquin, Jean-Pierre |
| Předmět: |
|
| Zdroj: |
Nature Communications; 9/21/2023, Vol. 14 Issue 1, p1-20, 20p |
| Abstrakt: |
The ERG (ETS-related gene) transcription factor is linked to various types of cancer, including leukemia. However, the specific ERG domains and co-factors contributing to leukemogenesis are poorly understood. Drug targeting a transcription factor such as ERG is challenging. Our study reveals the critical role of a conserved amino acid, proline, at position 199, located at the 3' end of the PNT (pointed) domain, in ERG's ability to induce leukemia. P199 is necessary for ERG to promote self-renewal, prevent myeloid differentiation in hematopoietic progenitor cells, and initiate leukemia in mouse models. Here we show that P199 facilitates ERG's interaction with the NCoR-HDAC3 co-repressor complex. Inhibiting HDAC3 reduces the growth of ERG-dependent leukemic and prostate cancer cells, indicating that the interaction between ERG and the NCoR-HDAC3 co-repressor complex is crucial for its oncogenic activity. Thus, targeting this interaction may offer a potential therapeutic intervention. ETS transcription factor ERG has been implicated in numerous cancers, including leukemia. Here, the authors show that ERG interaction with the NCoR-HDAC3 co-repressor complex is essential for its leukemogenic activity. Highlighting this interaction as a potential therapeutic target, HDAC3 inhibition led to reduced growth of ERG-dependent leukemia cells in vitro and in vivo. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink